Limitless Potential.
Precision Design.
Enduring Impact.
Aiming to transform the treatment of autoimmune diseases, including type 1 diabetes, and cancer by developing allogeneic, iPSC-derived cell therapies.
PRESS RELEASES + EVENTS
view all
July 09, 2026
Century Therapeutics Selected for Oral Presentations of CNTY-813 Preclinical Data at EASD 2026 and Breakthrough T1D® Clinical & Research Congress 2026
PHILADELPHIA, July 09, 2026 (GLOBE NEWSWIRE) — Century Therapeutics, Inc. (‘Century’, NASDAQ: IPSC), a biotechnology…
June 08, 2026
New CNTY-813 Preclinical Data Demonstrate Durable Glucose Control, Immune Evasion Under Alloimmune Pressure, and Scalable Manufacturing at ADA 2026
Advancing CNTY-813 as a potential functional cure in Type 1 Diabetes CNTY-813 iPSC-derived islet replacement…
About us
We are building an industry-leading, allogeneic, iPSC-derived cell therapy platform for autoimmune diseases, including type 1 diabetes, and cancer.
OUR SCIENCE
We are leveraging the unlimited self-renewing capacity of induced pluripotent stem cells (iPSC) and cutting-edge cellular engineering and manufacturing technologies to develop fit-for-purpose products with functionalities designed to overcome the limitations of existing cell therapies.
